Cyclacel Non Current Liabilities Total vs Total Current Liabilities Analysis
CYCC Stock | USD 2.00 0.07 3.38% |
Cyclacel Pharmaceuticals financial indicator trend analysis is way more than just evaluating Cyclacel Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclacel Pharmaceuticals is a good investment. Please check the relationship between Cyclacel Pharmaceuticals Non Current Liabilities Total and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.
Non Current Liabilities Total vs Total Current Liabilities
Non Current Liabilities Total vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclacel Pharmaceuticals Non Current Liabilities Total account and Total Current Liabilities. At this time, the significance of the direction appears to have strong relationship.
The correlation between Cyclacel Pharmaceuticals' Non Current Liabilities Total and Total Current Liabilities is 0.76. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Cyclacel Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Cyclacel Pharmaceuticals' Non Current Liabilities Total and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Cyclacel Pharmaceuticals are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Non Current Liabilities Total i.e., Cyclacel Pharmaceuticals' Non Current Liabilities Total and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | 0.76 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Non Current Liabilities Total
Total Current Liabilities
Total Current Liabilities is an item on Cyclacel Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cyclacel Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Cyclacel Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclacel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.At present, Cyclacel Pharmaceuticals' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.04, whereas Selling General Administrative is forecasted to decline to about 5.9 M.
2023 | 2024 (projected) | Discontinued Operations | 17.1K | 30.4K | Cost Of Revenue | 31K | 29.5K |
Cyclacel Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Cyclacel Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cyclacel Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 15.3M | 36.8M | 42.6M | 27.5M | 8.8M | 8.4M | |
Total Stockholder Equity | 11.7M | 33.3M | 37.3M | 15.5M | 607K | 576.7K | |
Retained Earnings | (357.6M) | (366.1M) | (385.0M) | (406.2M) | (428.3M) | (406.9M) | |
Common Stock Shares Outstanding | 54.4K | 242.2K | 595.1K | 657.6K | 850.8K | 893.4K | |
Liabilities And Stockholders Equity | 15.3M | 36.8M | 42.6M | 27.5M | 8.8M | 8.4M | |
Other Stockholder Equity | 370.1M | 400.1M | 423.0M | 414.0M | 429.8M | 284.3M | |
Total Liab | 3.6M | 3.5M | 5.3M | 12.0M | 8.2M | 14.1M | |
Other Current Liab | 1.5M | 2.0M | 3.2M | 4.8M | 4.6M | 3.4M | |
Total Current Liabilities | 2.4M | 2.5M | 5.3M | 7.4M | 8.2M | 5.8M | |
Property Plant And Equipment Net | 1.3M | 1.3M | 94K | 174K | 102K | 96.9K | |
Net Debt | (10.7M) | (32.3M) | (36.5M) | (18.2M) | (3.3M) | (3.5M) | |
Accounts Payable | 890K | 514K | 2.1M | 2.6M | 3.5M | 2.2M | |
Cash | 11.9M | 33.4M | 36.6M | 18.3M | 3.4M | 3.2M | |
Non Current Assets Total | 1.3M | 1.3M | 1.6M | 3.1M | 1.4M | 1.7M | |
Non Currrent Assets Other | (1.3M) | (1.3M) | 1.6M | 2.9M | 1.3M | 1.3M | |
Cash And Short Term Investments | 11.9M | 33.4M | 36.6M | 18.3M | 3.4M | 3.2M | |
Non Current Liabilities Total | 1.2M | 1.1M | 30K | 4.6M | 37K | 35.2K | |
Other Current Assets | 103K | 66K | 79K | 6.1M | 1.1M | 1.0M | |
Property Plant And Equipment Gross | 1.3M | 1.3M | 94K | 174K | 522K | 839.0K | |
Total Current Assets | 14.0M | 35.5M | 40.9M | 24.4M | 7.4M | 7.1M | |
Accumulated Other Comprehensive Income | (819K) | (746K) | (748K) | (1.3M) | (908K) | (953.4K) | |
Common Stock | 17K | 6K | 10K | 4.5M | 1K | 950.0 | |
Net Receivables | 1.3M | 1.3M | 3.7M | 5.6M | 2.9M | 2.7M | |
Inventory | 703K | 684K | 577K | (5.6M) | (5.1M) | (4.8M) | |
Property Plant Equipment | 27K | 106K | 94K | 174K | 156.6K | 148.8K | |
Retained Earnings Total Equity | (342.5M) | (349.8M) | (357.6M) | (366.1M) | (329.5M) | (345.9M) | |
Net Tangible Assets | 11.7M | 33.3M | 37.3M | 15.5M | 17.8M | 23.9M | |
Capital Surpluse | 365.1M | 365.8M | 370.1M | 400.1M | 460.1M | 394.6M | |
Non Current Liabilities Other | 124K | 100K | 1.2M | 1.1M | 1.2M | 1.3M | |
Net Invested Capital | 11.7M | 33.3M | 37.3M | 20.0M | 607K | 576.7K | |
Net Working Capital | 11.6M | 33.0M | 35.6M | 17.0M | (717K) | (681.2K) | |
Capital Stock | 17K | 6K | 10K | 4.5M | 1K | 950.0 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cyclacel Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cyclacel Pharmaceuticals' short interest history, or implied volatility extrapolated from Cyclacel Pharmaceuticals options trading.
Pair Trading with Cyclacel Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclacel Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Cyclacel Stock
0.75 | EGRX | Eagle Pharmaceuticals | PairCorr |
0.78 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
Moving against Cyclacel Stock
0.68 | QLI | Qilian International | PairCorr |
0.68 | SNDL | SNDL Inc Financial Report 20th of May 2024 | PairCorr |
0.62 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
0.43 | IMCC | Im Cannabis Corp | PairCorr |
The ability to find closely correlated positions to Cyclacel Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclacel Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclacel Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclacel Pharmaceuticals to buy it.
The correlation of Cyclacel Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclacel Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclacel Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclacel Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.Note that the Cyclacel Pharmaceuticals information on this page should be used as a complementary analysis to other Cyclacel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Cyclacel Stock analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Cyclacel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (26.75) | Revenue Per Share 0.494 | Return On Assets (0.86) | Return On Equity (2.73) |
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.